- Home
- New LDL-C Efficacy Studies
- TEMPO Results: LDL-C Efficacy
- TEMPO Results: Attainment of LDL-C <100 mg/dL
- TEMPO Results: Hypothetical Patient Case
- EZ-PATH Results: LDL-C Efficacy
- EZ-PATH Results: Attainment of LDL-C <70 mg/dL
- EZ-PATH Results: Hypothetical Patient Case
- Information About Titration
- Selected Statin Titration Studies
- Titration: 1-Year Retrospective Data
- Titration: Process-of-Care Study
- Learn About ZETIA
- Head-to-Head Comparison of Treatment Strategies
- LDL-C Efficacy: Coadministration With Simvastatin
- LDL-C Efficacy: Coadministration With Atorvastatin
- Hypothetical Patient Case Studies
- LDL-C Efficacy of Monotherapy
- TG Efficacy
- HDL-C Efficacy
- Coadministration With Fenofibrate
- Mechanism of Action
- LDL-C Efficacy: Patients Aged <65 and ≥65 Years
- Safety Profile, Tolerability, and Dosing
- Selected Safety Information
- Safety Profile and Tolerability: Patients Aged <65 and ≥65 Years
- Dosage: Once-Daily Tablet
- Clinical Studies
- MileStones Program
- Journal Reprints
- Managed Care Information
- Formulary Status
- Medicare Part D Formulary Status
- Physician Resources
- Merck OnCall ®
- Call Me Back
- eMedical Forums
- Request More Information
- Clinical Slide Sets
- Order Samples
- Patient Education Materials
- Prescribing Information
- Patient Product Information
- Patient Site for ZETIA
- Physician Site for VYTORIN® (ezetimibe / simvastatin)
Copyright © Merck/Schering-Plough Pharmaceuticals, 2008. All rights reserved.
20850964(1)-11/08-ZET